Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease

M. P. Corder; T. E. Elliott; L. C. Maguire; J. T. Leimert; S. K. Panther; P. A. Lachenbruch

Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease

M. P. Corder, T. E. Elliott, L. C. Maguire, J. T. Leimert, S. K. Panther, P. A. Lachenbruch

Family Medicine and Community Health (Duluth)

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.

Original language	English (US)
Pages (from-to)	763-766
Number of pages	4
Journal	Cancer Treatment Reports
Volume	63
Issue number	5
State	Published - 1979

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{09df10dcb44d4b739cc9973f613faf8a,

title = "Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease",

abstract = "A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.",

author = "Corder, {M. P.} and Elliott, {T. E.} and Maguire, {L. C.} and Leimert, {J. T.} and Panther, {S. K.} and Lachenbruch, {P. A.}",

year = "1979",

language = "English (US)",

volume = "63",

pages = "763--766",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease

AU - Corder, M. P.

AU - Elliott, T. E.

AU - Maguire, L. C.

AU - Leimert, J. T.

AU - Panther, S. K.

AU - Lachenbruch, P. A.

PY - 1979

Y1 - 1979

N2 - A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.

AB - A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.

UR - http://www.scopus.com/inward/record.url?scp=0018649858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018649858&partnerID=8YFLogxK

M3 - Article

C2 - 455312

AN - SCOPUS:0018649858

SN - 0361-5960

VL - 63

SP - 763

EP - 766

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 5

ER -

Phase II study of cis-dichlorodiammineplatinum(II) in stage IVB Hodgkin's disease

Abstract

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this